Benoxaprofen

Benoxaprofen
Two-dimensional monochrome diagram showing the structure of the molecule of benoxaprofen, using the hexagonal style to depict a chemical compound.
Benoxaprofen molecule
Clinical data
Trade namesOpren, Oraflex
ATC code
Legal status
Legal status
  • Withdrawn
Identifiers
  • 2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.051.864 Edit this at Wikidata
Chemical and physical data
FormulaC16H12ClNO3
Molar mass301.73 g·mol−1
3D model (JSmol)
  • O=C(O)C(c1cc2nc(oc2cc1)c3ccc(Cl)cc3)C
  • InChI=1S/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20) checkY
  • Key:MITFXPHMIHQXPI-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Benoxaprofen, also known as benoxaphen, is a chemical compound with the formula C16H12ClNO3. It is a non-steroidal anti-inflammatory drug (NSAID) of the arylpropionic acid class, and was marketed under the brand name Opren in the United Kingdom and Europe by Eli Lilly and Company (commonly referred to as Lilly), and as Oraflex in the United States of America (USA). Lilly suspended sales of Oraflex in 1982 after reports from the British government and the United States Food and Drug Administration (US FDA) of adverse effects and deaths linked to the drug.